Combination Chemotherapy With or Without Whole-Body Hyperthermia in Treating Patients With Recurrent Ovarian Epithelial Fallopian Tube or Peritoneal Cancer

  • participants needed
  • sponsor
    Ludwig-Maximilians - University of Munich
Updated on 7 November 2020
B. Hildebrandt, MD
Primary Contact
Charite University Hospital - Campus Virchow Klinikum (8.8 mi away) Contact
+3 other location
combination chemotherapy
tumor cells
fallopian tube
gynecologic cancer
peritoneal cancer


RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Hyperthermia therapy kills tumor cells by heating them to several degrees above body temperature. Combining hyperthermia with chemotherapy may kill more tumor cells. It is not yet known if chemotherapy is more effective with or without whole-body hyperthermia therapy in treating gynecologic cancer. PURPOSE: Randomized phase II/III trial to compare the effectiveness of chemotherapy with or without whole-body hyperthermia in treating patients who have recurrent ovarian epithelial, fallopian tube, or peritoneal cancer.


OBJECTIVES: - Compare the time to progressive disease in patients with recurrent ovarian epithelial, fallopian tube, or extraovarian peritoneal cancer treated with carboplatin and ifosfamide with or without whole body hyperthermia. - Compare the response rate, duration of response, and survival time of patients treated with these regimens. - Compare the effect on the presence of disseminated tumor cells in bone marrow in patients treated with these regimens. - Compare the toxicity of these regimens in these patients. - Assess quality of life of patients treated with these regimens. OUTLINE: This is a phase II safety and efficacy study followed by a phase III randomized, open-label, multicenter study. - Phase II: Patients receive ifosfamide IV over 1 hour and carboplatin IV over 20 minutes on day 1. Patients also undergo whole body hyperthermia for at least 1 hour on day 1. Treatment repeats every 28 days for 6 courses in the absence of disease progression or unacceptable toxicity. - Phase III (after successful treatment of 15 patients in phase II): Patients are stratified according to disease-free interval (6-12 months vs more than 12 months), measurable disease (bidimensionally measurable vs measurable by other clinical means), and disease recurrence (first recurrence vs second or greater recurrence). Patients are randomized to 1 of 2 treatment arms. - Arm I: Patients receive ifosfamide, carboplatin, and whole body hyperthermia as in phase II. - Arm II: Patients receive ifosfamide and carboplatin as in arm I. - In both arms, treatment repeats every 28 days for 6 courses in the absence of disease progression or unacceptable toxicity. Quality of life is assessed before each course, 4 weeks after the last course, and then every 3 months for 2 years. Patients are followed at 4 weeks and then every 3 months for 2 years. PROJECTED ACCRUAL: A total of 15 patients will be accrued for phase II of this study. A total of 226 patients (113 per treatment arm) will be accrued for phase III of this study within 2 years.

Condition Fallopian Tube Cancer, Ovarian Cancer
Treatment hyperthermia treatment, ifosfamide, carboplatin
Clinical Study IdentifierNCT00045461
SponsorLudwig-Maximilians - University of Munich
Last Modified on7 November 2020


How to participate?

Step 1 Connect with a site
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact


Preferred Language
Other Language
Please verify that you are not a bot.

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note